BRD4 and chronic obstructive pulmonary disease: The observed reduction in neutrophil adhesion, adhesion marker mRNA levels and inflammatory secretion was sufficient to demonstrate differences between treatment with budesonide (Fig. 4a3), which has been noted as clinically ineffective for COPD, and a novel bromodomain-containing protein 4 (BRD4) inhibitor [76].